Assignee
ARROWHEAD PHARMACEUTICALS INC
US76 patents
Top patents by PatentIndex Score
US10450565B2Oct 22, 2019
Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
ARROWHEAD PHARMACEUTICALS INC15 citations94
US10130651B2Nov 20, 2018
RNAi Therapy for Hepatitis B Virus Infection
ARROWHEAD PHARMACEUTICALS INC22 citations94
US11203756B2Dec 21, 2021
Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
ARROWHEAD PHARMACEUTICALS INC5 citations84
US10294474B2May 21, 2019
Targeting ligands
ARROWHEAD PHARMACEUTICALS INC15 citations84
US10597657B2Mar 24, 2020
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
ARROWHEAD PHARMACEUTICALS INC6 citations83
US10287582B2May 14, 2019
Organic compositions to treat HSF1-related diseases
ARROWHEAD PHARMACEUTICALS INC3 citations83
US10246709B2Apr 2, 2019
Targeting ligands for therapeutic compounds
ARROWHEAD PHARMACEUTICALS INC10 citations83
US10780108B2Sep 22, 2020
RNAi agents for Hepatitis B virus infection
ARROWHEAD PHARMACEUTICALS INC5 citations82
US10662427B2May 26, 2020
Compositions and methods for inhibiting gene expression of LPA
ARROWHEAD PHARMACEUTICALS INC6 citations82
US9932586B2Apr 3, 2018
Compositions and methods for inhibiting gene expression of LPA
ARROWHEAD PHARMACEUTICALS INC9 citations82
US10240153B2Mar 26, 2019
Organic compositions to treat APOC3-related diseases
ARROWHEAD PHARMACEUTICALS INC7 citations80
US12188017B2Jan 7, 2025
Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin
ARROWHEAD PHARMACEUTICALS INC1 citations73
US11884920B2Jan 30, 2024
Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
ARROWHEAD PHARMACEUTICALS INC2 citations73
US10995335B2May 4, 2021
RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use
ARROWHEAD PHARMACEUTICALS INC3 citations73
US10806750B2Oct 20, 2020
RNAi therapy for hepatitis B virus infection
ARROWHEAD PHARMACEUTICALS INC3 citations73
US10544418B2Jan 28, 2020
RNAi inhibition of alpha-ENaC expression
ARROWHEAD PHARMACEUTICALS INC1 citations73
US10308941B2Jun 4, 2019
Compositions and methods for inhibiting gene expression of factor XII
ARROWHEAD PHARMACEUTICALS INC4 citations73
US11590156B2Feb 28, 2023
RNAi agents for hepatitis B virus infection
ARROWHEAD PHARMACEUTICALS INC2 citations72
US11517584B2Dec 6, 2022
RNAi agents for Hepatitis B virus infection
ARROWHEAD PHARMACEUTICALS INC2 citations72
US11384355B2Jul 12, 2022
Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin
ARROWHEAD PHARMACEUTICALS INC3 citations72
US11214801B2Jan 4, 2022
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
ARROWHEAD PHARMACEUTICALS INC3 citations72
USRE48345EDec 8, 2020
Compositions and methods for inhibiting gene expression of hepatitis B virus
ARROWHEAD PHARMACEUTICALS INC3 citations72
US11180529B2Nov 23, 2021
Alpha-v beta-6 integrin ligands and uses thereof
ARROWHEAD PHARMACEUTICALS INC3 citations71
US11174481B2Nov 16, 2021
Targeting ligands
ARROWHEAD PHARMACEUTICALS INC3 citations71
US10927373B2Feb 23, 2021
Compositions and methods for inhibiting gene expression of Hif2alpha
ARROWHEAD PHARMACEUTICALS INC2 citations71
US11629349B2Apr 18, 2023
RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
ARROWHEAD PHARMACEUTICALS INC3 citations70
US11549112B1Jan 10, 2023
RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
ARROWHEAD PHARMACEUTICALS INC3 citations70
US10538765B2Jan 21, 2020
Organic compositions to treat EPAS1-related diseases
ARROWHEAD PHARMACEUTICALS INC1 citations70
US10316316B2Jun 11, 2019
Compositions for targeted delivery of siRNA
ARROWHEAD PHARMACEUTICALS INC1 citations69
US11597701B2Mar 7, 2023
Integrin ligands and uses thereof
ARROWHEAD PHARMACEUTICALS INC2 citations68
US12441756B2Oct 14, 2025
5′-cyclo-phosphonate modified nucleotides
ARROWHEAD PHARMACEUTICALS INC0 citations62
US12365899B2Jul 22, 2025
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
ARROWHEAD PHARMACEUTICALS INC0 citations62
US12116573B2Oct 15, 2024
Targeting ligands for therapeutic compounds
ARROWHEAD PHARMACEUTICALS INC0 citations62
US12091661B2Sep 17, 2024
Organic compositions to treat HSF1-related diseases
ARROWHEAD PHARMACEUTICALS INC0 citations62
US11534453B2Dec 27, 2022
RNAi therapy for hepatitis B virus infection
ARROWHEAD PHARMACEUTICALS INC0 citations62
US11208662B2Dec 28, 2021
RNAi inhibition of alpha-ENaC expression
ARROWHEAD PHARMACEUTICALS INC0 citations62
US11091761B2Aug 17, 2021
Organic compositions to treat HSF1-related diseases
ARROWHEAD PHARMACEUTICALS INC0 citations62
US11078227B2Aug 3, 2021
5′-cyclo-phosphonate modified nucleotides
ARROWHEAD PHARMACEUTICALS INC0 citations62
US9752152B2Sep 5, 2017
Organic compositions to treat beta-ENaC-related diseases
ARROWHEAD PHARMACEUTICALS INC1 citations62
US11840688B2Dec 12, 2023
Compositions and methods for inhibiting gene expression of Hif2alpha
ARROWHEAD PHARMACEUTICALS INC0 citations61
US11214802B2Jan 4, 2022
RNAi agents for inhibiting expression of alpha-ENaC and methods of use
ARROWHEAD PHARMACEUTICALS INC0 citations61
US10590416B2Mar 17, 2020
RNAi agents for inhibiting expression of alpha-ENaC and methods of use
ARROWHEAD PHARMACEUTICALS INC1 citations61
US12582718B2Mar 24, 2026
Integrin targeting ligands and uses thereof
ARROWHEAD PHARMACEUTICALS INC0 citations60
US12173086B2Dec 24, 2024
Alpha-v beta-6 integrin ligands and uses thereof
ARROWHEAD PHARMACEUTICALS INC0 citations60
US12065458B2Aug 20, 2024
Trialkyne linking agents and methods of use
ARROWHEAD PHARMACEUTICALS INC0 citations60
US11920134B2Mar 5, 2024
Compositions and methods for inhibiting expression of RRM2 genes
ARROWHEAD PHARMACEUTICALS INC0 citations60
US11492624B2Nov 8, 2022
RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1
ARROWHEAD PHARMACEUTICALS INC1 citations60
US11912997B2Feb 27, 2024
RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use
ARROWHEAD PHARMACEUTICALS INC0 citations59
US11261444B2Mar 1, 2022
Organic compositions to treat EPAS1-related diseases
ARROWHEAD PHARMACEUTICALS INC0 citations59
US11066667B2Jul 20, 2021
Organic compositions to treat APOC3-related diseases
ARROWHEAD PHARMACEUTICALS INC1 citations59
Showing the top 50 of 76 patents by PatentIndex Score.